CONTEXT AND OBJECTIVE: Polymorphisms in genes involved in folate metabolism may modulate the maternal risk of Down syndrome (DS). This study evaluated the influence of a 19-base pair (bp) deletion polymorphism in intron-1 of the dihydrofolate reductase (DHFR) gene on the maternal risk of DS, and investigated the association between this polymorphism and variations in the concentrations of serum folate and plasma homocysteine (Hcy) and plasma methylmalonic acid (MMA).
were the first to observe an increased risk of chromosome non-disjunction due to abnormal folate metabolism, and this is responsible for abnormalities in the pattern of deoxyribonucleic acid (DNA) methylation.
Folate plays an essential role in several complex metabolic pathways, including those leading to DNA synthesis or conversion of homocysteine (Hcy) to methionine, which is then used to form the main DNA methylating agent: S-adenosyl methionine (SAM). 4 Studies have shown that polymorphisms in genes encoding enzymes involved in this metabolic pathway, and higher concentrations of Hcy and lower folate concentrations, modulate the maternal risk factor for DS. [5] [6] [7] [8] The dihydrofolate reductase (DHFR) gene encodes an enzyme that catalyzes the conversion of dihydrofolate (DHF) into tetrahydrofolate (THF). It is also needed for the intracellular conversion of synthetic folic acid (which is consumed in supplements and fortified foods) to DHF and THF, which are the forms that participate in folate and Hcy metabolism. 9 Johnson et al. 10 described a 19-base pair (bp) deletion polymorphism in intron-1 of the DHFR gene and hypothesized that this polymorphism could be functional because the deletion removes a possible transcription factor binding site that affects gene regulation.
A study on the mothers of individuals with spina bifida showed that the messenger ribonucleic acid (mRNA) expression of the DHFR gene was 50% higher in the del/del genotype than in the ins/ ins genotype. 11 Moreover, in a study on women with breast cancer, Xu et al. 12 also observed mRNA concentrations that were 2.4 and 4.8 times higher in individuals with the ins/del and del/del genotypes, respectively, in comparison with individuals with the ins/ins genotype.
This polymorphism has been correlated with modulation of the metabolites involved in the folate pathway. Gellekink et al. 13 reported that the del/del genotype was associated with lower plasma Hcy concentrations, but did not find any association between this genotype and concentrations of serum and erythrocyte folate. Another study did not find any effect on Hcy concentration, but found increased plasma and erythrocyte folate levels in del/del individuals. 9 To the best of our knowledge, no published studies have evaluated the association of 19-bp deletion polymorphism in intron-1 of the DHFR gene with the maternal risk of DS.
OBJECTIVES
This study aimed to evaluate the influence of the 19-bp deletion polymorphism in intron-1 of the DHFR gene on the maternal risk of DS and to investigate the association between this polymorphism and variations in the concentrations of serum folate and plasma Hcy and methylmalonic acid (MMA), an indicator of vitamin B 12 status.
METHODS
This analytical cross-sectional study was carried out at Faculdade de Medicina de São José do Rio Preto (Famerp) and was composed of a case group formed by 105 mothers of DS children with karyotypically confirmed free trisomy 21 and a control group consisting of 184 mothers with healthy offspring and no experience of miscarriages. Informed consent was obtained from all these volunteers.
The mothers' median ages at delivery (maternal age) and when the blood samples were obtained (age at presentation) were 30.4 years (range 12.9-46.3 years) and 43.1 years (range 22.5-69.3 years) in the case group, respectively, and 26.4 years (range 15.4-40.7 years) and 36.1 years (13.2-68.8 years) in the control group. The maternal age was calculated as the age of the mother at the birth of the DS child for the case group, and the age at the birth of the last child for the control group.
Fasting blood samples were collected for molecular and biochemical analysis (serum folate and plasma Hcy and MMA). DNA extraction was performed as previously described by Miller et al. 14 and the 19-bp deletion polymorphism in DHFR gene was analyzed by means of the polymerase chain reaction (PCR) using the difference in the size of fragments to determinate the genotypes, using primer sequences described by Dulucq et al. 15 The PCR-amplified fragments were analyzed by means of electrophoresis in 6% polyacrylamide gel.
Folate was quantified by means of chemiluminescence (Immulite Kit, DPC Medlab, Brazil) and liquid chromatography-tandem mass spectrometry was used to determine the plasma Hcy and MMA concentrations, as previously described. [16] [17] [18] The existence of Hardy-Weinberg equilibrium was tested using the chi-square test, and genotype frequencies among the case and control mothers were compared by means of the likelihood ratio test and logistic regression. Mood's median test was used to investigate the association between the polymorphism in the DHFR gene and variations in the serum folate and plasma Hcy and MMA concentrations. P values ≤ 0.05 were taken to be statistically significant. Table 1 presents the allele and genotype frequencies of 19-bp deletion polymorphism in the DHFR gene in the case and control groups. The allele frequencies were in Hardy-Weinberg equilibrium in both groups, and there were no differences in allele and genotype frequencies be tween the DS and control mothers. There were no significant differences in the distributions of serum folate and plasma Hcy and MMA concentrations between the genotypes of the case and control groups (P > 0.05) ( Table 2 . Distribution of serum folate, plasma homocysteine (Hcy) and plasma methylmalonic acid (MMA) concentrations according to genotypes of the 19-bp deletion polymorphism in intron-1 of the dihydrofolate reductase (DHFR) gene, in the case and control groups of mothers result in aberrant DNA methylation, point mutations, chromosome breakage, defective chromosome recombination and aneuploidy of chromosome 21. [19] [20] [21] Folate metabolism plays an important role in the synthesis of nucleotides and of SAM, which is the main donor of methyl groups for DNA, protein and phospholipid methylation reactions. 22 Many genes are involved in these metabolic pathways and, in 1999, James et al. 3 hypothesized that abnormalities in DNA methylation are a potential causative mechanism of meiotic non-disjunction. Their report stimulated considerable investigation into the possible role of folate metabolism in relation to the risk of having a DS child, and several studies have found this association. [5] [6] [7] [8] 23, 24 One important gene that is involved in this metabolism is DHFR, which encodes the enzyme responsible for reducing folic acid in THF. 9 A common polymorphism in this gene, 19-bp deletion polymorphism in intron-1, has been correlated with modulation of the maternal risk of neural tube defects (NTDs), 10, 11 and of the concentrations of the metabolites involved in the folate pathway. 9, 13, 25 Originally, Johnson et al. 10 observed that the del/del genotype was related to increased risk of having offspring with spina bifida. On the other hand, another study has suggested that the del/del genotype has a protective effect and decreases the maternal risk of spina bifida, 11 while yet another study reported no effect. 26 Thus, the contribution of the 19-bp deletion polymorphism in intron-1 of the DHFR gene towards the risk of NTDs remains a matter of controversy.
RESULTS
Considering the high frequency of DS cases in families with higher risk of NTDs, and vice versa, 27 and the fact that both diseases are influenced by the same genetic determinants of folate metabolism, 28 it is possible that the 19-bp deletion polymorphism in intron-1 of the DHFR gene modulates the maternal risk of DS. However, in the present study, no association between this polymorphism and the maternal risk of DS was observed. In addition, no association was observed between the 19-bp deletion polymorphism of the DHFR gene and the folate, Hcy and MMA concentrations in the present study, although the presence of the polymorphic allele has been associated with increased concentrations of serum and erythrocyte folate, and reduction in the concentration of plasma Hcy in previous studies. 9, 13, 25 The variations between studies may have been caused by nutritional and ethnic differences between the populations studied, as well as differences in sample sizes and other genetic factors.
One of the limitations of our study is that serum folate was quantified instead of erythrocyte folate. The erythrocyte folate content represents the time average of the folate concentrations occurring at the genesis of each red cell and is therefore less susceptible to rapid changes in diet. 29, 30 One study observed a significant difference in erythrocyte folate quantification between case and control mothers, which was not observed when quantifying serum folate. 31 However, quantification of erythrocyte folate is more complex to perform 29.30 and, for this reason, many studies have measured serum folate. 5, [32] [33] [34] In addition, a recent study has indicated that serum folate assays provide information that is equivalent to erythrocyte folate measurements for attempting to determine folate deficiency. 30 
CONCLUSIONS
In this study, no evidence for an association between the 19-bp deletion polymorphism in intron-1 of the DHFR gene and the maternal risk of DS was observed. Moreover, this polymorphism was not related to variations in the concentrations of serum folate and plasma Hcy and MMA in the study population.
